Shouyao Holdings (Beijing) Co. LTD
Shouyao Holdings (Beijing) Co. LTD
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies | ALK Positive Advanced Malignancies | Recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT07810933 | |
| Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-06-16 | NCT06031558 | |
| A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors | Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion | Recruiting | Phase 1 | 2026-04-27 | NCT07469982 | |
| Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | Advanced Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2025-05-14 | NCT06970132 | |
| A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 3 | 2024-02-12 | NCT06254599 |